CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 963 enrolled
Drug / intervention
Peginterferon alpha +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01098097
NCT01098097N/ACompleted

Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin

Merck Sharp & Dohme LLC·observational·Posted Apr 2, 2010·Updated Nov 26, 2014

In Brief

An observational study evaluating Peginterferon alpha and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 963 participants.

Detailed Summary

To study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2, 2010
Enrollment StartJun 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.3 years ago

Interventions

Peginterferon alphabiological

Peginterferon alpha given in combination with ribavirin according to local labeling guidelines

Ribavirindrug

Ribavirin given in combination with peginterferon alpha according to local labeling guidelines